Search Results
Oct 20, 2025, 08:30 ET AbelZeta Announces Late-Breaking Poster Presentation at ACR Convergence 2025 of First-in-Human Phase I Trial of anti-CD20/BCMA Bispecific CAR-T Therapy in Patients with Refractory Autoimmune Diseases
ROCKVILLE, Md., Oct. 20, 2025 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of
More news about: AbelZeta Pharma, Inc.
Oct 20, 2025, 08:22 ET Abundant Venture Partners Accelerates National Growth with New Health System Alliance Members and Pediatric Cohort Launch
owners of opportunities uncovered via the Abundant Platform. "At Lurie Children's, we've long focused on innovation within pediatrics," Tom Shanley, MD, President and CEO, Ann & Robert H. Lurie Children's Hospital of Chicago. "We've been particularly impressed by the perspective Abundant brings to
More news about: Abundant Venture Partners
Oct 20, 2025, 08:00 ET Oshi Health Launches Access+ to Help GI Practices Expand Capacity, Boost Revenue and Retention, and Improve Patient Outcomes
services. "Access+ was designed to put GI practices back in control of their schedules, growth, and patient outcomes," said Sameer Berry, MD, MBA, Co-founder & Chief Medical Officer, Oshi Health. "We're not asking practices to adopt a new model. We're helping them scale the one they already
More news about: Oshi Health
Oct 20, 2025, 08:00 ET DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives
dialyzers. "DaVita is committed to advancing the treatment of kidney failure through innovative science," said Francesca Tentori, MD, vice president of outcomes research and patient empowerment for DaVita. "By exploring how middle-molecule removal may influence long-term health as well
More news about: DaVita
Oct 20, 2025, 08:00 ET Lower mortgage rates extend housing momentum into fall
Baltimore, MD
More news about: Zillow
Oct 20, 2025, 07:00 ET Milvus Advanced Raises Seed Round to Scale Industrial-Scale Substitution of Critical Elements With Next-Generation Nanoalloy Technologies
Ventures, includes participation from LQD Ventures, Übermorgen, Tuesday Capital, Mark Leslie Enterprises, van Den Bosch Dynasty Fund, Bluebirds, Md One, EQT Foundation, and returning investor Lowercarbon Capital.
More news about: Milvus Advanced
Oct 20, 2025, 07:00 ET Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
prior systemic therapy for advanced disease. The final clinical results were presented on behalf of the DeFianCe study investigators by Zev Wainberg, MD, Professor of Medicine and Co-Director of the GI Oncology Program at UCLA in a Mini Oral session at the European Society for Medical Oncology (ESMO) Congress
More news about: Leap Therapeutics, Inc.
Oct 20, 2025, 06:00 ET ORVANA STRENGTHENS POSITION IN ITS TAGUAS PROPERTY IN ARGENTINA BY REACQUIRING 1% NSR INTEREST
Forward-looking statements are based on current expectations and involve risks and uncertainties as described in Orvana's Annual Information Form and MD&A, available at www.sedarplus.ca. Actual results may differ materially from those expressed or implied
More news about: Orvana Minerals Corp.
Oct 20, 2025, 05:00 ET FDA Grants Orphan Drug Designation to Cellenkos' CK0803 Tregs for Treatment of Amyotrophic Lateral Sclerosis
underscores the importance of bringing novel, transformative treatment options to patients suffering from this rare disease", said Dr. Simrit Parmar, MD, Founder of Cellenkos. Dr. Parmar is also faculty at Texas A&M School of Engineering Medicine. "We aim to deliver a transformative therapeutic that
More news about: Cellenkos, Inc.
Oct 20, 2025, 05:00 ET Nathalie Kelley Strikes Gold, Sustainably: Actress Designs Jewelry to Raise Awareness on Mercury-Free Gold Mining
Earth's Benefit at the Current in New York City on November 3rd, 2025, with special guest Nathalie Kelley. Pure Earth will honor Atul Gawande, MD, MPH, renowned surgeon, New York Times best-selling author, and public health leader, with the Impact Award at the event. Other special guests include
More news about: Pure Earth
Oct 20, 2025, 02:37 ET Immunotherapy After Surgery Shows Promise in Treating Rare, Aggressive Skin Cancer
Miller, MD, PhD, at the Dana-Farber Cancer Institute in Boston; Brian Gastman, MD, and Donald Eicher, MD, at the Cleveland Clinic; Charles Hsu, MD, PhD, at the University of Arizona in Tucson; Gary Cohen, MD, at the Greater Baltimore Medical Center in Towson, Maryland; Pauline Funchain, MD, at Stanford
More news about: NYU Langone Health System
Oct 19, 2025, 19:30 ET IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
vasculitis or occlusive vasculitis, and no increased risk of intraocular inflammation. Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research at Sierra Eye Associates, Clinical Professor at University of Nevada, Reno, Nevada "The
More news about: Astellas Pharma Inc.
Oct 19, 2025, 10:49 ET iOncologi Secures Foundational U.S. Patent as Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival with Cancer Immunotherapy
2025 Supporting this mechanistic foundation, new translational data were presented by Dr. Adam Grippin of MD Anderson Cancer Center on Sunday, October 19, 2025 (LBA54) during the European Society for Medical Oncology (ESMO) Annual Congress in Berlin.
More news about: iOncologi, Inc.
Oct 19, 2025, 10:30 ET VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
first‑line therapies" said Timothy A. Yap, M.B.B.S.., Ph.D., Head of Clinical Development in the Therapeutics Discovery Division at the University of Texas MD Anderson Cancer Center and lead clinical investigator for the study. "We are encouraged by the clinically meaningful disease control that was achieved
More news about: Vivace Therapeutics, Inc.
Oct 19, 2025, 09:17 ET HDAI to announce AI tools that drive quality outcomes at HLTH 2025
moderated by Ellen Knapp, PhD, senior intelligence analyst at CB Insights. She will be joined by Nassib Chamoun, CEO and founder of HDAI, Jill Kalman, MD, EVP and Chief Medical Officer and Physician-in-chief at Northwell Health, Jenn Hall, PhD, Chief of Data Science and Analytics at the American Heart Association
More news about: Health Data Analytics Institute
Oct 18, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in LifeMD, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFMD
Quarter 2025 Results." This announcement quoted Chief Financial Officer Marc Benathen as stating that due to "some temporary challenges facing our Rex MD business," which he claimed were "largely resolved," that the Company was "revising our full year 2025 guidance for revenue and adjusted EBITDA to reflect
More news about: Pomerantz LLP
Oct 18, 2025, 05:03 ET GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
ability to accurately predict where in the body the cancer signal comes from also helps to guide a more efficient diagnostic workup," said Josh Ofman, MD, MSHS, President at GRAIL. "These results are extremely compelling as approximately three-quarters of the Galleri-detected cancers do not have recommended
More news about: GRAIL, Inc.
Oct 18, 2025, 03:00 ET Florida Cancer Specialists & Research Institute Shaping the Future of Cancer Care at Global Congress
Lucio N. Gordan, MD, FCS president & managing physician. The following physician leader is first author of an oral presentation at the
More news about: Florida Cancer Specialists & Research Institute
Oct 17, 2025, 17:39 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
diabetes face an increased risk of cardiovascular events, underscoring the need for therapies that go beyond managing blood sugar," said John B. Buse, MD, PhD, Distinguished Professor of Medicine, Director of the UNC Diabetes Care Center, and Steering Committee Co-Chair of the SOUL trial. "Having an oral
More news about: Novo Nordisk
Oct 17, 2025, 17:15 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
diabetes face an increased risk of cardiovascular events, underscoring the need for therapies that go beyond managing blood sugar," said John B. Buse, MD, PhD, Distinguished Professor of Medicine, Director of the UNC Diabetes Care Center, and Steering Committee Co-Chair of the SOUL trial. "Having an
More news about: Novo Nordisk
Oct 17, 2025, 15:36 ET At 2025 STAT Summit, Guests including Joe Kennedy III, AMA President, Former NIH Leaders, Explore CRISPR, Pharma, Public Health, and More
here, courtesy of Jeff Pinette for STAT The STAT Summit is presented by Merck, The University of Texas MD Anderson Cancer Center, Biogen, Genetech, Genmab, Medidata, Viiv Healthcare, Chan Zuckerberg Biohub Network, Klick Health, and Zeno.
More news about: STAT
Oct 17, 2025, 14:02 ET The Inner Circle acknowledges Ilene Fennoy, MD, MPH, as a Pinnacle Professional Member Inner Circle of Excellence
NEW YORK, Oct. 17, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Ilene Fennoy, MD, MPH is acknowledged as a Pinnacle Professional Member Inner Circle of Excellence for her contributions to Pediatric Endocrinology and Child Health Advocacy.
More news about: The Inner Circle
Oct 17, 2025, 12:16 ET BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients
Kuehl include Ramon Diaz-Arrastia, MD, PhD, Professor of Neurology, Director, Clinical TBI Research Center, University of Pennsylvania, Perelman School of Medicine; Martin Than, MD, Director of Emergency Medicine Research, Christchurch, New Zealand; Chad Canon, MD, Professor of Emergency Medicine, University
More news about: BRAINBox Solutions, Inc.
Oct 17, 2025, 10:00 ET Boehringer's HERNEXEOS® demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
which in the past has made it hard to find a targeted treatment offering significant clinical benefit," said the presenting author, Prof. Sanjay Popat, MD, PhD, Consultant Medical Oncologist, Head of the Lung Unit, and Lead for the Lung Cancer Research Programme at the Royal Marsden Hospital. "A response
More news about: Boehringer Ingelheim
Oct 17, 2025, 09:30 ET Sage Care Emerges From Stealth with $20M in Funding for an AI-Powered Care Navigation System
access to the right care at the right time is inefficient for healthcare providers and often results in suboptimal patient experience", said Dr. Ash Goel MD, Senior Vice President and Chief Information Officer at Bronson Healthcare. "The care navigation operating system, Sage, addresses these complexities
More news about: Sage Care